Swedbank AB Decreases Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Swedbank AB lessened its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 40.8% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 8,297 shares of the company’s stock after selling 5,715 shares during the quarter. Swedbank AB’s holdings in Neurocrine Biosciences were worth $1,133,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently modified their holdings of the business. Commerce Bank boosted its position in Neurocrine Biosciences by 2.6% in the third quarter. Commerce Bank now owns 4,199 shares of the company’s stock worth $484,000 after purchasing an additional 108 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its holdings in shares of Neurocrine Biosciences by 2.7% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,302 shares of the company’s stock worth $496,000 after buying an additional 113 shares during the last quarter. Brooklyn Investment Group grew its position in Neurocrine Biosciences by 99.1% during the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock valued at $32,000 after buying an additional 115 shares during the period. Tealwood Asset Management Inc. raised its position in Neurocrine Biosciences by 1.0% in the fourth quarter. Tealwood Asset Management Inc. now owns 11,911 shares of the company’s stock worth $1,626,000 after acquiring an additional 118 shares during the period. Finally, MassMutual Private Wealth & Trust FSB boosted its stake in Neurocrine Biosciences by 42.0% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 531 shares of the company’s stock valued at $72,000 after acquiring an additional 157 shares during the last quarter. 92.59% of the stock is owned by institutional investors.

Analyst Ratings Changes

NBIX has been the subject of several research analyst reports. William Blair restated an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Barclays boosted their target price on Neurocrine Biosciences from $160.00 to $165.00 and gave the company an “overweight” rating in a research note on Monday, December 23rd. Piper Sandler reiterated an “overweight” rating and set a $160.00 price target on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. HC Wainwright restated a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Finally, Raymond James reiterated an “outperform” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences has an average rating of “Moderate Buy” and an average target price of $166.10.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, CEO Kyle Gano sold 65,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $141.50, for a total value of $9,197,500.00. Following the transaction, the chief executive officer now owns 135,392 shares in the company, valued at approximately $19,157,968. The trade was a 32.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kevin Charles Gorman sold 146,105 shares of the business’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $149.46, for a total value of $21,836,853.30. Following the transaction, the director now owns 514,596 shares in the company, valued at approximately $76,911,518.16. This represents a 22.11 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 214,799 shares of company stock valued at $31,513,583. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Trading Down 1.0 %

Shares of NBIX opened at $151.82 on Monday. Neurocrine Biosciences, Inc. has a 12-month low of $110.95 and a 12-month high of $157.98. The company has a market cap of $15.37 billion, a PE ratio of 40.70 and a beta of 0.33. The stock has a 50-day moving average price of $136.97 and a 200-day moving average price of $131.42.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.